Globally Recognized Nephrologist Joins Dicerna™ to Support Continued Development of DCR-PHXC for the Treatment of Primary Hyperoxaluria
Dicerna™ Hires Industry Veterans to Lead Regulatory Affairs and Patient Advocacy
Dicerna™ Appoints Rob Ciappenelli Chief Commercial Officer
Dicerna™ Bolsters Leadership Team to Support Continued Growth
We interfere with disease
We use RNA interference, or RNAi, to create medicines that silence the genes that cause or contribute to disease. Our goal is to provide life-changing therapies to people living with rare and common diseases.